Company Overview of Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. Its lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute. Syndax Pharmaceuticals, Inc. was founded in 2005 and is...
400 Totten Pond Road
Waltham, MA 02451
Founded in 2005
Key Executives for Syndax Pharmaceuticals, Inc.
Co-Founder and Chief Technology Officer
Compensation as of Fiscal Year 2014.
Syndax Pharmaceuticals, Inc. Key Developments
Syndax Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 12:30 PM
Jun 21 14
Syndax Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 12:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.
Syndax Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 11:30 AM
May 21 14
Syndax Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 11:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Arlene M. Morris, Chief Executive Officer, President and Director, John S. Pallies, Chief Financial Officer and Treasurer, Peter Ordentlich, Co-Founder and Chief Technology Officer.
Syndax Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Mar 27 14
Syndax Pharmaceuticals, Inc. filed its S-1 on Mar 27, 2014 for the period ending Dec 31, 2013. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 13, 2013